John Maraganore’s decision to step down as Alnylam Pharmaceuticals’ CEO after almost 20 years came as a shock to people outside of the company — enough to send the company’s stock tumbling by more than 16% that day.
But it was a shock, too, to people within Alnylam, Maraganore recalled at the 2021 STAT Summit in Boston on Tuesday. Including, even, his successor as CEO, Yvonne Greenstreet.
Greenstreet, who will take over as CEO in January, was “excited,” “nervous,” and “a little bit angry,” when he broke the news over dinner at Sorellina, Maraganore said.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
